KZIA Kazia Therapeutics Ltd

13 February 2013

The Manager

Company Announcements Office

ASX Limited

20 Bridge Street

SYDNEY  NSW  2000

Dear Sir

Notice under Section 708A of the Corporations Act

On   13   February   2013   Novogen   Ltd   (ASX:   NRT)   issued   a   total   of   13,600,000  fully   paid

ordinary shares ( Shares ).

NRT hereby gives notice under section 708A(5)(e) of the Corporations Act ( Act ) that:

1.

NRT issued the Shares without disclosure under Part 6D.2 of the Corporations Act;

2.

As at the date of this notice NRT has complied with:

(a)

the provisions of Chapter 2M of the Act as they apply to NRT; and

(b)

section 674 of the Act; and

3.

As  at  the  date  of  this  notice  there  is  no  excluded  information  to  be  provided  in

accordance with section 708A(7) and (8) of the Act.

Yours sincerely

Andrew Bursill

Company Secretary

Novogen Ltd

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade on both

the Australian Stock Exchange (symbol ‘ NRT ’ ) and NASDAQ (symbol ‘ NVGN ’ ).  The

Company is based in Sydney, Australia and is focused on the development of a family of

novel anti-cancer drugs based on super-benzopyran and ‘ stealth ’ drug technologies. The

Company ’ s inaugural drug candidate is CS-6.

862643_1_novogen - notice under section 708a of the corporations act

1

About CS-6

CS-6 belongs to a new class of drug candidates known (structurally) as super-

benzopyrans displaying potent anti-cancer activity and demonstrating increased bio-

availability to cancer cells ( ‘ stealth ’ technology). CS-6 shows broad anti-proliferative

and cytotoxic activity against human cancer cells, with particular activity against human

glioblastoma cells. CS-6 also has been designed deliberately to meet the major known

criteria for crossing the blood-brain barrier, and for that reason is being developed as a

first-line for the treatment of glioblastoma multiforme, the main form of primary brain

cancer.

Further information

Contact Dr Graham Kelly, Chief Executive Officer.

T:  (61 2) 9878 0088

M: (61) 0459 200 095

E: Graham.Kelly@novogen.com

Further information is available on the Company ’ s web site, www.novogen.com

862643_1_novogen - notice under section 708a of the corporations act

2

Appendix 3B

New issue announcement

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement,

application for quotation of additional securities

and agreement

Information or documents not available now must be given to ASX as soon as available.  Information and

documents given to ASX become ASX ’ s property and may be made public.

Introduced 01/07/96  Origin: Appendix 5  Amended   01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

NOVOGEN LIMITED

ABN

37 063 259 754

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1

⁺ Class   of   ⁺ securities   issued   or   to    Ordinary Shares

be issued

2

Number    of   ⁺ securities   issued   or    13,600,000

to     be     issued     (if     known)     or

of

the    Ordinary Shares

+ securities       (eg,       if       options,

exercise   price   and   expiry   date;   if

partly     paid      + securities,     the

amount     outstanding     and     due

dates

for

payment;

if

+ convertible

securities,

the

conversion    price    and  dates    for

conversion)

+ See chapter 19 for defined terms.

01/08/2012

Appendix 3B  Page 1

not rank equally, please state:

    the date from which they do

    the     extent     to     which     they

participate     for     the     next

dividend,    (in    the    case    of    a

trust,

distribution)

or

interest payment

    the   extent   to   which   they   do

not   rank   equally,   other   than

in      relation      to      the      next

dividend,       distribution       or

interest payment

5

Issue price or consideration

As  part  of  consideration  for  acquisition  of

Triaxial Pharmaceuticals Pty Ltd shares.

6

Purpose of the issue

As  part  of  consideration  for  acquisition  of

(If    issued    as    consideration    for    Triaxial Pharmaceuticals Pty Ltd shares.

the   acquisition   of   assets,   clearly

identify those assets)

6a

Is  the  entity  an    ⁺ eligible  entity    No

that     has     obtained     security

holder approval under rule 7.1A?

If   Yes, complete sections 6b – 6h

in   relation   to   the    + securities   the

subject   of   this   Appendix   3B ,   and

comply with section 6i

6b

The   date   the   security   holder    N/A

resolution    under    rule    7.1A    was

passed

6c

Number     of      ⁺ securities     issued    15,279,782

without security   holder approval

under rule 7.1

+ See chapter 19 for defined terms.

Appendix 3B Page 2

01/08/2012

Appendix 3B

New issue announcement

6d

Number     of      ⁺ securities     issued    N/A

with   security   holder   approval

under rule 7.1A

6e

Number     of      ⁺ securities     issued    N/A

with   security   holder   approval

under      rule      7.3,      or      another

specific   security   holder   approval

(specify date of meeting)

6f

Number    of    securities    issued    N/A

under an exception in rule 7.2

6g

If    securities    issued    under    rule    N/A

7.1A,   was   issue   price   at least 75%

of    15    day    VWAP    as    calculated

under  rule  7.1A.3?    Include  the

issue     date     and     both     values.

Include   the   source   of   the   VWAP

calculation.

6h

If    securities  were  issued  under    N/A

rule

7.1A

for

non-cash

consideration,    state    date    on

which

valuation

of

consideration   was   released   to

ASX Market Announcements

6i

Calculate   the   entity ’ s   remaining    Refer Annexure 1

7

Dates    of     entering       ⁺ securities    13 February 2013

into    uncertificated    holdings    or

despatch of certificates

Number

⁺ Class

8

Number     and

⁺ class     of     all    117,405,676

Ordinary Shares

⁺ securities     quoted     on     ASX

( including     the     securities     in

section 2 if applicable)

+ See chapter 19 for defined terms.

01/08/2012

Appendix 3B  Page 3

Unlisted options

⁺ securities    not    quoted    on  ASX

with various exercise

( including     the     securities     in

dates and prices.

section 2 if applicable)

10

Dividend   policy   (in   the   case   of   a    N/A

trust,   distribution   policy)   on   the

increased capital (interests)

Part 2 - Bonus issue or pro rata issue

11

Is     security     holder     approval

required?

12

Is   the   issue renounceable   or   non-

renounceable?

13

Ratio   in   which   the    ⁺ securities

will be offered

14

⁺ Class   of  ⁺ securities   to   which   the

offer relates

15

⁺ Record       date     to     determine

entitlements

16

Will      holdings      on      different

17

Policy  for  deciding  entitlements

in relation to fractions

18

Names   of   countries   in   which   the

entity   has    ⁺ security   holders   who

will    not    be    sent    new    issue

documents

Note:   Security   holders   must   be   told   how   their

entitlements are to be dealt with.

Cross reference: rule 7.7.

19

Closing      date      for      receipt      of

acceptances or renunciations

+ See chapter 19 for defined terms.

Appendix 3B Page 4

1/1/2003

Appendix 3B

New issue announcement

20

Names of any underwriters

21

Amount   of   any   underwriting   fee

or commission

22

Names   of   any   brokers   to   the

issue

23

Fee or commission payable to the

broker to the issue

24

Amount     of     any     handling     fee

payable   to   brokers   who   lodge

acceptances  or   renunciations   on

28

Date   rights   trading   will   begin   (if

applicable)

29

Date    rights    trading  will  end    (if

applicable)

30

How   do      ⁺ security   holders   sell

their   entitlements   in   full   through

a broker?

31

How   do      ⁺ security   holders   sell

part      of      their      entitlements

through   a   broker   and   accept   for

the balance?

+ See chapter 19 for defined terms.

01/08/2012

Appendix 3B  Page 5

Appendix 3B

New issue announcement

32

How do   ⁺ security holders dispose

of  their  entitlements  (except  by

sale through a broker)?

33

⁺ Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34

Type of securities

( tick one )

(a)

Securities described in Part 1

(b)

All other securities

Example:   restricted   securities   at   the   end   of   the   escrowed   period,   partly   paid   securities   that   become   fully   paid,

employee   incentive   share   securities   when   restriction   ends,   securities   issued   on   expiry   or   conversion   of   convertible

securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick   to   indicate   you   are   providing   the   information   or

documents

35

 If   the   ⁺ securities   are   ⁺ equity   securities, the   names   of   the   20   largest holders   of   the

additional    ⁺ securities,   and   the   number   and   percentage   of   additional    ⁺ securities

held by those holders

36

 If   the  ⁺ securities   are  ⁺ equity   securities,   a   distribution   schedule   of   the   additional

⁺ securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

37

 A copy of any trust deed for the additional   ⁺ securities

+ See chapter 19 for defined terms.

Appendix 3B Page 6

01/08/2012

Appendix 3B

New issue announcement

Entities that have ticked box 34(b)

38

Number    of    securities    for    which

⁺ quotation is sought

39

Class     of     ⁺ securities     for     which

quotation is sought

40

Do   the  ⁺ securities   rank   equally   in

all     respects     from     the     date     of

allotment  with  an  existing    ⁺ class

of quoted   ⁺ securities?

If   the   additional   securities   do   not

rank equally, please state:

    the date from which they do

    the    extent    to    which    they

participate      for      the      next

dividend,   (in   the   case   of   a

trust,  distribution)   or   interest

payment

    the    extent    to    which    they    do

not   rank   equally,   other   than   in

relation  to  the   next   dividend,

distribution

or

interest

payment

41

Reason  for   request   for   quotation

now

Example:   In   the   case   of   restricted   securities,   end

of restriction period

(if     issued     upon     conversion     of

⁺ securities      quoted      on      ASX

( including   the   securities   in   clause

38)

+ See chapter 19 for defined terms.

01/08/2012

Appendix 3B  Page 7

Appendix 3B

New issue announcement

Quotation agreement

1

⁺ Quotation   of   our   additional    ⁺ securities   is   in   ASX ’ s   absolute   discretion.    ASX

may quote the   ⁺ securities on any conditions it decides.

2

We warrant the following to ASX.



The   issue   of   the  ⁺ securities   to   be   quoted   complies   with   the   law   and   is

not for an illegal purpose.



There    is    no    reason    why    those    ⁺ securities    should    not    be    granted

⁺ quotation.



An   offer   of   the    ⁺ securities   for   sale   within   12   months   after   their   issue

will   not   require   disclosure   under   section   707(3)   or   section   1012C(6)   of

the Corporations Act.

Note:   An   entity   may   need   to   obtain   appropriate   warranties   from   subscribers   for   the   securities   in   order   to   be

able to give this warranty



Section   724   or   section   1016E of the Corporations Act does not apply to

any  applications  received  by   us  in  relation  to  any   ⁺ securities  to  be

quoted   and   that   no-one   has   any   right   to   return   any    ⁺ securities   to   be

quoted   under   sections   737,   738   or   1016F   of   the Corporations Act at the

time that we request that the   ⁺ securities be quoted.



If we are a trust, we warrant that no person has the right to return the

⁺ securities to be quoted under section 1019B of the Corporations Act at

the time that we request that the   ⁺ securities be quoted.

3

We will indemnify ASX to the fullest extent permitted by law in respect of any

claim,   action   or   expense   arising   from   or   connected   with   any   breach   of   the

warranties in this agreement.

4

We   give   ASX   the   information   and   documents   required   by   this   form.   If   any

information    or    document    not    available    now,    will    give    it    to    ASX    before

⁺ quotation   of   the    ⁺ securities   begins.    We   acknowledge   that   ASX   is   relying   on

the   information   and   documents.    We   warrant   that   they   are   (will   be)   true   and

complete.

Sign here:

............................................................

Date: ..13/02/2013....

(Company secretary)

Print name:

..Andrew Bursill......................................

== == == == ==

+ See chapter 19 for defined terms.

Appendix 3B Page 8

01/08/2012

Appendix 3B

New issue announcement

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for

⁺ eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital

   Step 1: Calculate “ A ” , the base figure from which the placement

capacity is calculated

Insert number of fully paid ordinary

102,125,894

securities on issue 12 months before date

of issue or agreement to issue

Add the following:

   •    Number of fully paid ordinary securities

issued in that 12 month period under an

exception in rule 7.2

-

   •    Number of fully paid ordinary securities

issued in that 12 month period with

shareholder approval

   •    Number of partly paid ordinary securities

that became fully paid in that 12 month

period

Note:

  •    Include only ordinary securities here –

other classes of equity securities cannot

be added

  •    Include here (if applicable) the securities

the subject of the Appendix 3B to which

this form is annexed

  •    It may be useful to set out issues of

securities on different dates as separate

line items

Subtract the number of fully paid ordinary

-

securities cancelled during that 12 month

period

   “ A ”

102,125,894

+ See chapter 19 for defined terms.

01/08/2012

Appendix 3B Page 9

Appendix 3B

New issue announcement

   Step 2: Calculate 15% of “ A ”

   “ B ”

0.15

[Note: this value cannot be changed]

Multiply “ A ” by 0.15

15,318,884

Step 3: Calculate “ C ” , the amount of placement capacity under rule

7.1 that has already been used

Insert number of equity securities issued or

agreed to be issued in that 12 month period

not counting those issued:

   •    Under an exception in rule 7.2

(15,279,782)

   •    Under rule 7.1A

   •    With security holder approval under rule

7.1 or rule 7.4

Note:

  •    This applies to equity securities, unless

specifically excluded – not just ordinary

securities

  •    Include here (if applicable ) the

securities the subject of the Appendix

3B to which this form is annexed

  •    It may be useful to set out issues of

securities on different dates as separate

line items

   “ C ”

(15,279,782)

   Step 4: Subtract “ C ” from [ “ A ” x “ B ” ] to calculate remaining

placement capacity under rule 7.1

   “ A ” x 0.15

15,318,884

Note: number must be same as shown in

Step 2

Subtract “ C ”

(15,279,782)

Note: number must be same as shown in

Step 3

Total [ “ A ” x 0.15] – “ C ”

39,102

[Note: this is the remaining placement

capacity under rule 7.1]

+ See chapter 19 for defined terms.

Appendix 3B Page 10

01/08/2012

Appendix 3B

New issue announcement

Part 2

Rule 7.1A – Additional placement capacity for eligible entities

   Step 1: Calculate “ A ” , the base figure from which the placement

capacity is calculated

   “ A ”

N/A

Note: number must be same as shown in

Step 1 of Part 1

   Step 2: Calculate 10% of “ A ”

   “ D ”

0.10

Note: this value cannot be changed

Multiply “ A ” by 0.10

N/A

   Step 3: Calculate “ E ” , the amount of placement capacity under rule

Appendix 3B Page 11

Appendix 3B

New issue announcement

   Step 4: Subtract “ E ” from [ “ A ” x “ D ” ] to calculate remaining

placement capacity under rule 7.1A

   “ A ” x 0.10

N/A

Note: number must be same as shown in

Step 2

Subtract “ E ”

N/A

Note: number must be same as shown in

Step 3

Total [ “ A ” x 0.10] – “ E ”

N/A

Note: this is the remaining placement

capacity under rule 7.1A

+ See chapter 19 for defined terms.

Appendix 3B Page 12

01/08/2012